Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in China
723 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleCancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis
- Where
- Nanjing
- Age
- 18 years to 80 years
- People
- 240
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT06162767 - Phase 2Not yet taking people in ChinaNeoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT06310473 - Phase 2Taking peoplePembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 25
- Run by
- Tongji University
See details and how to joinNCT06304350 - Phase 2Taking peopleAdjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
- Where
- Shanghai
- Age
- 20 years to 80 years
- People
- 114
- Run by
- Fudan University
See details and how to joinNCT05975749 - Phase 2Taking peopleConsolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
- Where
- Guangzhou
- Age
- 70 years to 85 years
- People
- 140
- Run by
- Sun Yat-sen University
See details and how to joinNCT06187597 - Phase 1/2Enrolling by invitationNeoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Qiu Guoqin
See details and how to joinNCT06303583 - Phase 3Taking peopleA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 490
- Run by
- Beijing Konruns Pharmaceutical Co., Ltd.
See details and how to joinNCT06194734 - Phase 3Taking peopleM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 486
- Run by
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
See details and how to joinNCT06177041 - No phaseTaking peopleA Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Fujian Medical University
See details and how to joinNCT06277024 - No phaseTaking peopleDistribution of Lymph Node Metastases in Esophageal Carcinoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 5,000 worldwide
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT03222895 - Phase 2Taking peopleInduction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
- Where
- Fuzhou
- Age
- 18 years to 70 years
- People
- 93
- Run by
- Fuzhou General Hospital
See details and how to joinNCT05515315 - Phase 2Not yet taking people in ChinaEfficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study
- Where
- Changzhou
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Wu Jun
See details and how to joinNCT06241469 - Phase 2Taking peopleCamrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 68
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06163729 - Phase 3Taking peopleComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Where
- Chengdu, Dalian, Guangzhou, Guiyang, Harbin, Kunming, Nanchang, Shanghai, Wuhan, Zhengzhou
- Age
- 18 years to 75 years
- People
- 540
- Run by
- Sun Yat-sen University
See details and how to joinNCT05918094 - No phaseTaking peopleThe Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)
- Where
- Changsha
- Age
- 18 years to 75 years
- People
- 200
- Run by
- Second Xiangya Hospital of Central South University
See details and how to joinNCT05967910 - Phase 2Taking peoplePerioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
- Where
- Hangzhou, Lishui, Ningbo, Taizhou
- Age
- 18 years to 80 years
- People
- 314
- Run by
- Yu jiren
See details and how to joinNCT05872685 - Phase 3Taking peopleSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 360
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT06123494 - No phaseTaking peoplePrediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Ruijin Hospital
See details and how to joinNCT05140746 - Phase 2Taking peopleA Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 31
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT06190639 - No phaseEnrolling by invitationA Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Xiaomeng Zheng
See details and how to joinNCT06160557 - Phase 2Not yet taking people in ChinaCVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 98
- Run by
- Convalife (Shanghai) Co., Ltd.
See details and how to joinNCT06183736 - No phaseTaking peopleWhole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
- Where
- Hefei
- Age
- 18 years to 85 years
- People
- 70
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT05833594 - Phase 2Not yet taking people in ChinaNeoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT06178211 - Phase 2/3Taking peopleKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
- Where
- Beijing
- Age
- 18 years and over
- People
- 286
- Run by
- Shanghai JMT-Bio Inc.
See details and how to joinNCT05427383 - Phase 1/2Taking peopleImmunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT06173986